News

The trial was a multi-center double-blind, randomized, placebo-controlled parallel group study. Patients in the study had advanced cancer and were experiencing pain that was not responding adequately to

Although the board of Oxford BioMedica confirmed that the discussions were taking place in a recent statement, it also stressed that these discussions are at an early stage

“Lipin regulates how the body stores and burns fat. Our findings suggest that differences in lipin levels may play a role in why some people are more prone

The two companies have announced a collaborative agreement whereby the clinical facilities, trial site networks, proprietary technologies and scientific expertise of each company would be made available to

The study of the dipeptidyl peptidase-IV (DP-IV) inhibitor, PSN9301, will enroll approximately 60 patients into a two-week in-house dosing and monitoring protocol which will be conducted in Berlin,

Alagebrium has demonstrated an ability to reverse erectile dysfunction (ED) in a preclinical model of ED in diabetic rats, through what appears to be a unique mechanism of

Xyrem (sodium oxybate) is currently marketed as the first and only approved treatment for cataplexy, a sudden loss of muscle tone that is a debilitating symptom of narcolepsy.

Under the terms of the agreement, the University of Maryland Greenebaum Cancer Center (UMGCC) will be granted access to the diverse libraries designed by Chemical Diversity (ChemDiv). In

“This action by the US Patent and Trademark Office (PTO) is very important to Spectrum as it will provide US market exclusivity through 2022,” stated Dr Rajesh Shrotriya,